Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.2 USD | +0.37% | +4.31% | +20.34% |
Apr. 26 | Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 | MT |
Apr. 26 | Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 | MT |
Evolution of the average Target Price on Merck & Co., Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Merck & Co., Inc.
Cantor Fitzgerald | |
BMO Capital | |
Leerink Partners | |
Zacks Investment Research | |
Berenberg Bank | |
Truist Securities | |
Wells Fargo Securities | |
Societe Generale | |
UBS | |
Goldman Sachs | |
Barclays | |
Jefferies & Co. | |
Deutsche Bank Securities | |
BofA Securities | |
TD Cowen | |
Morgan Stanley | |
HSBC | |
Atlantic Equities | |
Citigroup | |
Guggenheim | |
Credit Suisse | |
JPMorgan Chase | |
Wolfe Research | |
SVB Securities LLC | |
Daiwa Securities | |
Cowen | |
SVB Leerink | |
Argus | |
RBC Capital Markets | |
RBC | Randall Stanicky |
JPMORGAN |
EPS Revisions
- Stock Market
- Equities
- MRK Stock
- Consensus Merck & Co., Inc.